Breast Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Breast Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 3 (2006), Issue 5 (May)

1. Prognosis and management of patients with node-negative invasive breast carcinoma that is 1 cm or smaller in size (stage 1; T1a,bN0M0): a review of the literature.
   J Clin Oncol, 24(13): 2113-22. [Abstract] [Full-text]
2. Changes in neurologic function tests may predict neurotoxicity caused by ixabepilone.
   J Clin Oncol, 24(13): 2084-91. [Abstract] [Full-text]
3. Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials.
   J Clin Oncol, 24(13): 2028-37. [Abstract] [Full-text]
4. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27.
   J Clin Oncol, 24(13): 2019-27. [Abstract] [Full-text]
5. Axillary sentinel lymph nodes can be falsely positive due to iatrogenic displacement and transport of benign epithelial cells in patients with breast carcinoma.
   J Clin Oncol, 24(13): 2013-8. [Abstract] [Full-text]
6. Hypoxia inhibits protein synthesis through a 4E-BP1 and elongation factor 2 kinase pathway controlled by mTOR and uncoupled in breast cancer cells.
   Mol Cell Biol, 26(10): 3955-65. [Abstract] [Full-text]
7. Non-small-cell lung cancer and breast carcinoma: chemotherapy and beyond.
   Lancet Oncol, 7(5): 416-24. [Abstract] [Full-text]
8. Image-guided breast brachytherapy: an alternative to whole-breast radiotherapy.
   Lancet Oncol, 7(5): 407-15. [Abstract] [Full-text]
9. Screening mammography and risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study.
   Lancet Oncol, 7(5): 402-6. [Abstract] [Full-text]
10. STAT 5a expression in the breast is maintained in secretory carcinoma, in contrast to other histologic types.
    Hum Pathol, 37(5): 586-92. [Abstract] [Full-text]
11. Metaplastic breast cancer: clinical significance.
    Am J Surg, 191(5): 657-64. [Abstract] [Full-text]
12. The evaluation and treatment implications of isolated pulmonary nodules in patients with a recent history of breast cancer.
    Am J Surg, 191(5): 641-5. [Abstract] [Full-text]
13. Outcomes among women younger than age 40 in a state breast cancer screening program.
    Am J Surg, 191(5): 635-40. [Abstract] [Full-text]
14. Transgenic introduction of androgen receptor into estrogen-receptor-, progesterone-receptor-, and androgen-receptor-negative breast cancer cells renders them responsive to hormonal manipulation.
    Am J Surg, 191(5): 576-80. [Abstract] [Full-text]
15. 3,3'-diindolylmethane and paclitaxel act synergistically to promote apoptosis in HER2/Neu human breast cancer cells.
    J Surg Res, 132(2): 208-13. [Abstract] [Full-text]
16. Elevated Golgi pH in breast and colorectal cancer cells correlates with the expression of oncofetal carbohydrate T-antigen.
    J Cell Physiol, 208(1): 167-74. [Abstract] [Full-text]
17. Satisfaction with prophylactic mastectomy and breast reconstruction in genetically predisposed women.
    Plast Reconstr Surg, 117(6): 1675-82; discussion 1683-4. [Abstract] [Full-text]
18. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial.
    J Natl Cancer Inst, 98(9): 599-609. [Abstract] [Full-text]
19. Baseline psychosocial predictors of survival in localised breast cancer.
    Br J Cancer, 94(9): 1245-52. [Abstract] [Full-text]
20. Oestrogen receptor beta and neoadjuvant therapy with tamoxifen: prediction of response and effects of treatment.
    Br J Cancer, 94(9): 1333-8. [Abstract] [Full-text]
21. Randomised trial: survival benefit and safety of adjuvant dose-dense chemotherapy for node-positive breast cancer.
    Br J Cancer, 94(9): 1237-44. [Abstract] [Full-text]
22. Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial.
    Br J Cancer, 94(9): 1233-6. [Abstract] [Full-text]
23. Risk of invasive breast carcinoma among women diagnosed with ductal carcinoma in situ and lobular carcinoma in situ, 1988-2001.
    Cancer, 106(10): 2104-12. [Abstract] [Full-text]
24. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial.
    Cancer, 106(10): 2095-103. [Abstract] [Full-text]
25. Impact of estrogen receptor expression and other clinicopathologic features on tamoxifen use in ductal carcinoma in situ.
    Cancer, 106(10): 2113-8. [Abstract] [Full-text]
26. ACTIBIND, an actin-binding fungal T2-RNase with antiangiogenic and anticarcinogenic characteristics.
    Cancer, 106(10): 2295-308. [Abstract] [Full-text]
27. Extracellular tumor DNA in plasma and overall survival in breast cancer patients.
    Genes Chromosomes Cancer, 45(7): 692-701. [Abstract] [Full-text]
28. Microarray-based survey of CpG islands identifies concurrent hyper- and hypomethylation patterns in tissues derived from patients with breast cancer.
    Genes Chromosomes Cancer, 45(7): 656-67. [Abstract] [Full-text]
29. A genome wide linkage search for breast cancer susceptibility genes.
    Genes Chromosomes Cancer, 45(7): 646-55. [Abstract] [Full-text]
30. Mitochondrial DNA mutations and mitochondrial DNA depletion in breast cancer.
    Genes Chromosomes Cancer, 45(7): 629-38. [Abstract] [Full-text]
31. Racial and ethnic disparities in breast cancer mortality: are we doing enough to address the root causes?
    J Clin Oncol, 24(14): 2170-8. [Abstract] [Full-text]
32. Unopposed estrogen therapy and the risk of invasive breast cancer.
    Arch Intern Med, 166(9): 1027-32. [Abstract] [Full-text]
33. Allelic imbalance of HER2 variant in sporadic breast and ovarian cancer.
    Cancer Genet Cytogenet, 167(1): 32-8. [Abstract] [Full-text]
34. Total-genome analysis of BRCA1/2-related invasive carcinomas of the breast identifies tumor stroma as potential landscaper for neoplastic initiation.
    Am J Hum Genet, 78(6): 961-72. [Abstract] [Full-text]
35. Dosimetric comparison of two different three-dimensional conformal external beam accelerated partial breast irradiation techniques.
    Int J Radiat Oncol Biol Phys, 65(2): 340-6. [Abstract] [Full-text]
36. Persistent seroma after intraoperative placement of MammoSite for accelerated partial breast irradiation: incidence, pathologic anatomy, and contributing factors.
    Int J Radiat Oncol Biol Phys, 65(2): 333-9. [Abstract] [Full-text]
37. Concurrent administration of adjuvant chemotherapy and radiotherapy after breast-conserving surgery enhances late toxicities: long-term results of the ARCOSEIN multicenter randomized study.
    Int J Radiat Oncol Biol Phys, 65(2): 324-32. [Abstract] [Full-text]
38. Serum C-peptide levels and breast cancer risk: results from the European Prospective Investigation into Cancer and Nutrition (EPIC).
    Int J Cancer, 119(3): 659-67. [Abstract] [Full-text]
39. Differential response to phytoestrogens in endocrine sensitive and resistant breast cancer cells in vitro.
    Int J Cancer, 119(3): 515-21. [Abstract] [Full-text]
40. Breast cancer in Belarus and Ukraine after the Chernobyl accident.
    Int J Cancer, 119(3): 651-8. [Abstract] [Full-text]
41. Two functionally relevant polymorphisms in the human progesterone receptor gene (+331 G/A and progins) and the predisposition for breast and/or ovarian cancer.
    Gynecol Oncol, 101(2): 287-95. [Abstract] [Full-text]
42. Histopathologic behavior of endometrial hyperplasia during tamoxifen therapy for breast cancer.
    Gynecol Oncol, 101(2): 269-73. [Abstract] [Full-text]
43. Statin use and breast cancer: prospective results from the Women's Health Initiative.
    J Natl Cancer Inst, 98(10): 700-7. [Abstract] [Full-text]
44. Effectiveness of radiation therapy for older women with early breast cancer.
    J Natl Cancer Inst, 98(10): 681-90. [Abstract] [Full-text]
45. Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients.
    J Natl Cancer Inst, 98(10): 671-80. [Abstract] [Full-text]
46. Identification of tetratricopeptide repeat domain 9, a hormonally regulated protein.
    Biochem Biophys Res Commun, 345(1): 310-7. [Abstract] [Full-text]
47. Adiponectin mediates antiproliferative and apoptotic responses in human MCF7 breast cancer cells.
    Biochem Biophys Res Commun, 345(1): 271-9. [Abstract] [Full-text]
48. HER2 and responsiveness of breast cancer to adjuvant chemotherapy.
    N Engl J Med, 354(20): 2103-11. [Abstract] [Full-text]
49. Dendritic cell immunotherapy for breast cancer.
    Expert Opin Biol Ther, 6(6): 591-604. [Abstract] [Full-text]
50. Endocrine-disrupting compounds and mammary gland development: early exposure and later life consequences.
    Endocrinology, 147(6): S18-24. [Abstract] [Full-text]
51. Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.
    J Clin Oncol, 24(15): 2276-82. [Abstract] [Full-text]
52. Genes associated with breast cancer metastatic to bone.
    J Clin Oncol, 24(15): 2261-7. [Abstract] [Full-text]
53. Study of failure pattern among high-risk breast cancer patients with or without postmastectomy radiotherapy in addition to adjuvant systemic therapy: long-term results from the Danish Breast Cancer Cooperative Group DBCG 82 b and c randomized studies.
    J Clin Oncol, 24(15): 2268-75. [Abstract] [Full-text]
54. A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system.
    J Pharmacol Exp Ther, 317(3): 1372-81. [Abstract] [Full-text]
55. Evaluation of a prospective scoring system designed for a multicenter breast MR imaging screening study.
    Radiology, 239(3): 677-85. [Abstract] [Full-text]
56. Proton MR spectroscopy with choline peak as malignancy marker improves positive predictive value for breast cancer diagnosis: preliminary study.
    Radiology, 239(3): 686-92. [Abstract] [Full-text]
57. Computer-aided detection of breast cancer: a cost-effectiveness study.
    Radiology, 239(3): 710-7. [Abstract] [Full-text]
58. Contrast-enhanced MR imaging of the breast at 3.0 and 1.5 T in the same patients: initial experience.
    Radiology, 239(3): 666-76. [Abstract] [Full-text]
59. Contrast-enhanced breast MRI in patients with suspicious microcalcifications on mammography: results of a multicenter trial.
    AJR Am J Roentgenol, 186(6): 1723-32. [Abstract] [Full-text]
60. Radiation benefit and risk at the assessment stage of the UK Breast Screening Programme.
    Br J Radiol, 79(942): 479-82. [Abstract] [Full-text]
61. Adjuvant aromatase inhibitor therapy for early breast cancer: A review of the most recent data.
    J Surg Oncol, 93(7): 585-92. [Abstract] [Full-text]
62. Predictors of invasive disease in breast cancer when core biopsy demonstrates DCIS only.
    J Surg Oncol, 93(7): 559-63. [Abstract] [Full-text]
63. Can axillary dissection be avoided in patients with sentinel lymph node metastasis?
    J Surg Oncol, 93(7): 550-8. [Abstract] [Full-text]
64. The ATM missense mutation p.Ser49Cys (c.146C>G) and the risk of breast cancer.
    Hum Mutat, 27(6): 538-44. [Abstract] [Full-text]
65. Differential polyamine analogue effects in four human breast cancer cell lines.
    Toxicology, 223(1): 71-81. [Abstract] [Full-text]
66. Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging.
    JAMA, 295(20): 2374-84. [Abstract] [Full-text]
67. Axillary lymph node count is lower after neoadjuvant chemotherapy.
    Am J Surg, 191(6): 827-9. [Abstract] [Full-text]
68. Carcinoid tumors in the breast.
    Am J Surg, 191(6): 799-805. [Abstract] [Full-text]
69. Prevention of nausea and vomiting following breast surgery.
    Am J Surg, 191(6): 767-72. [Abstract] [Full-text]
70. Sentinel lymph node positivity of patients with ductal carcinoma in situ or microinvasive breast cancer.
    Am J Surg, 191(6): 761-6. [Abstract] [Full-text]
71. Radiotherapy omission after breast-conserving surgery is associated with reduced breast cancer-specific survival in elderly women with breast cancer.
    Am J Surg, 191(6): 749-55. [Abstract] [Full-text]
72. Fluorodeoxyglucose positron emission tomography with sentinel lymph node biopsy for evaluation of axillary involvement in breast cancer.
    Br J Surg, 93(6): 707-12. [Abstract] [Full-text]
73. Growth inhibition of breast cancer cell lines overexpressing Her2/neu by a novel internalized fully human Fab antibody fragment.
    Cancer Immunol Immunother, 55(9): 1091-9. [Abstract] [Full-text]
74. AIB1 gene amplification and the instability of polyQ encoding sequence in breast cancer cell lines.
    BMC Cancer, 6: 111. [Abstract] [Full-text]
75. Quantitative reverse transcription-PCR assay for detection of mRNA encoding full-length human tissue kallikrein 7: prognostic relevance of KLK7 mRNA expression in breast cancer.
    Clin Chem, 52(6): 1070-9. [Abstract] [Full-text]
76. Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients.
    Cancer, 106(11): 2337-44. [Abstract] [Full-text]
77. Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: follow-up at 12 years.
    Cancer, 106(11): 2327-36. [Abstract] [Full-text]
78. Patterns and predictors of mammography utilization among breast cancer survivors.
    Cancer, 106(11): 2482-8. [Abstract] [Full-text]
79. Once daily, oral, outpatient quinolone monotherapy for low-risk cancer patients with fever and neutropenia: a pilot study of 40 patients based on validated risk-prediction rules.
    Cancer, 106(11): 2489-94. [Abstract] [Full-text]
80. Differences between first and subsequent rounds of the MRISC breast cancer screening program for women with a familial or genetic predisposition.
    Cancer, 106(11): 2318-26. [Abstract] [Full-text]
81. Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial.
    Cancer, 106(11): 2309-17. [Abstract] [Full-text]
82. Isolation by size of epithelial tumor cells in peripheral blood of patients with breast cancer: correlation with real-time reverse transcriptase-polymerase chain reaction results and feasibility of molecular analysis by laser microdissection.
    Hum Pathol, 37(6): 711-8. [Abstract] [Full-text]
83. c-Jun activation is associated with proliferation and angiogenesis in invasive breast cancer.
    Hum Pathol, 37(6): 668-74. [Abstract] [Full-text]
84. Breast cancer risk estimates for relatives of white and African American women with breast cancer in the Women's Contraceptive and Reproductive Experiences Study.
    J Clin Oncol, 24(16): 2498-504. [Abstract] [Full-text]
85. Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines.
    J Clin Oncol, 24(16): 2444-7. [Abstract] [Full-text]
86. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
    J Clin Oncol, 24(16): 2428-36. [Abstract] [Full-text]
87. Objective cancer-related variables are not associated with depressive symptoms in women treated for early-stage breast cancer.
    J Clin Oncol, 24(16): 2420-7. [Abstract] [Full-text]
88. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer.
    J Clin Oncol, 24(16): 2437-43. [Abstract] [Full-text]
89. High expression of ubiquitin carboxy-terminal hydrolase-L1 and -L3 mRNA predicts early recurrence in patients with invasive breast cancer.
    Cancer Sci, 97(6): 523-9. [Abstract] [Full-text]

© 2004-2008 Breast Cancer Research Today. All Rights Reserved.